CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare CAMP4 Therapeutics to similar businesses based on the strength of its institutional ownership, analyst recommendations, risk, profitability, earnings, dividends and valuation.
Profitability
This table compares CAMP4 Therapeutics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CAMP4 Therapeutics | -2,276.33% | -182.39% | -74.87% |
| CAMP4 Therapeutics Competitors | -12,516.26% | -215.37% | -31.41% |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for CAMP4 Therapeutics and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CAMP4 Therapeutics | 1 | 1 | 8 | 1 | 2.82 |
| CAMP4 Therapeutics Competitors | 9926 | 15341 | 45752 | 1601 | 2.54 |
CAMP4 Therapeutics currently has a consensus target price of $10.44, suggesting a potential upside of 160.92%. As a group, “Biotechnology” companies have a potential upside of 109.98%. Given CAMP4 Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe CAMP4 Therapeutics is more favorable than its competitors.
Volatility and Risk
CAMP4 Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, CAMP4 Therapeutics’ competitors have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.
Earnings and Valuation
This table compares CAMP4 Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| CAMP4 Therapeutics | $3.50 million | -$80.40 million | -1.87 |
| CAMP4 Therapeutics Competitors | $718.90 million | $8.79 million | -18.41 |
CAMP4 Therapeutics’ competitors have higher revenue and earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
47.8% of shares of all “Biotechnology” companies are held by institutional investors. 21.7% of CAMP4 Therapeutics shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
CAMP4 Therapeutics beats its competitors on 9 of the 13 factors compared.
CAMP4 Therapeutics Company Profile
CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
